As of September 30, 2025, the company had trailing 12-month revenue of $62.5K. Management has identified substantial doubt about the company's ability to continue as a going concern due to its accumulated net loss of $1,331,643 since inception. In March 2026, Goldenwell Biotech filed an NT 10-K notification indicating it could not timely compile its Form 10-K for the year ended December 31, 2025, and expects to file by April 15, 2026.
Cyborg Score Rationale
The company exhibits fundamental operational and financial challenges including minimal revenue generation, accumulated losses exceeding $1.3 million, acute cash constraints, and going concern doubts. Filing delays further suggest governance or operational strain.
Top Insights
Company is in development stage with negligible revenue ($62.5K in TTM as of Q3 2025) despite multi-year existence
Severe liquidity constraints with only $4,755 in cash as of September 2024 and negative working capital
Going concern warnings and substantial accumulated losses ($1.3M+) signal potential insolvency without capital infusion
Filing delays (March 2026 NT 10-K for 2025 10-K) indicate governance or resource constraints
Named Competitors
Nutritional Supplements — Global nutritional supplement and wellness products
Nutritional Supplements — Nutrition, weight management, and skin care products
Collagen-Based Supplements — Marine and bovine collagen peptide supplements
Dietary Supplements — Beauty and wellness supplements and skincare
Recent Developments
(March 2026) Filed late notice for 2025 Form 10-K; expected filing by April 15, 2026
(September 2024) Reported net loss of $103,962 for nine-month period with minimal cash balance of $4,755
(November 2024) Quarterly 10-Q filing revealed negative working capital of $(19,239)
Open the full interactive Goldenwell Biotech, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.